MPE webinar on ASH 2020 myeloma and AL amyloidosis highlightsAL amyloidosis, MPE, Myeloma8 December 2020
ASH 2020 | Certain people with blood cancers and COVID-19 infection vulnerable to severe illnessAL amyloidosis, Conferences, Myeloma6 December 2020
ASH 2020 | The phase III trial Apollo supports administering daratumumab subcutaneously instead of intravenously in relapsed or refractory myeloma patientsConferences, Myeloma5 December 2020
ASH 2020 | Visit our poster on myeloma patient information needs and preferences at ASH 2020!Conferences, MPE, Myeloma5 December 2020
ASCO and EHA highlights in myeloma and AL amyloidosisAL amyloidosis, Conferences, MPE, Myeloma, Videos20 July 2020
FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patientsAccess, Myeloma14 May 2020
MPE webinar on the impact of myeloma and AL amyloidosis in carers. What are the issues and challenges?AL amyloidosis, MPE, Myeloma8 May 2020
